New horizons in predictive drug metabolism and pharmacokinetics
General Material Designation
[Book]
First Statement of Responsibility
edited by Alan G.E. Wilson.
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Cambridge, UK
Name of Publisher, Distributor, etc.
Royal Society of Chemistry, [
Date of Publication, Distribution, etc.
2016]
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
(xxi, 422 pages .).
SERIES
Series Title
RSC drug discovery series.
CONTENTS NOTE
Text of Note
How physicochemical properties of drugs affect their metabolism and clearance; Role of solubility, permeability and adsorption in drug discovery in development; Models for nonspecific binding and partitioning; Cytochrome P450 mediated drug metabolism; Non-cytochrome P450 enzymes and glucuronidation; Metabolite profiling; Application of humanised and other transgenic models to predict human responses to drugs; Stem cells and drug metabolism; Chemically reactive versus stable drug metabolites: Role in adverse drug reactions; Integrating metabolism and toxicity properties; Metabolomics-based approaches to determine drug metabolite profiles; Drug-drug ineteractions: regulatory and theoretical considerations, and an industrial perspective; Drug-drug interactions: Computational approaches; Induction of hepatic cytochrome P450 enzymes: Importance in drug development and toxicity; Current status and implications of transporters: QSAR analysis method to evaluate drug-drug interactions of human bile salt export pump (ABCB11/BSEP) and prediction of intrahepatic cholestasis risk; Formulation of optimizing bioavailability; Systems pharmacology modelling; Pharmacokinetic-pharmacodynamic modelling in drug development with special reference to oncology;